<DOC>
	<DOCNO>NCT01365286</DOCNO>
	<brief_summary>The purpose study investigate heart rate lower efficacy respiratory safety ivabradine patient asthma COPD .</brief_summary>
	<brief_title>HR-lowering Efficacy Respiratory Safety Ivabradine Patients With Obstructive Airway Disease</brief_title>
	<detailed_description>In double blind , placebo-controlled , crossover study , 20 asthmatic 20 COPD patient receive ivabradine 7,5 mg b.i.d . placebo 5 day crossover manner . HR ECG holter monitoring , peak expiratory flow rate ( PEFR ) , symptom , rescue medication consumption AEs evaluate period treatment .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>document diagnosis asthma COPD accordance guideline stable condition , define disease without exacerbation least 1 month prior study enrolment mean HR holter ECG record â‰¥ 60 bpm disease exacerbation previous month inability understand instruction study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>asthma , chronic obstructive pulmonary disease , COPD , ivabradine , heart rate</keyword>
</DOC>